Health care costs for schizophrenia patients started on olanzapine versus risperidone

American Journal of Health-System Pharmacy

Volumn 62, Issue 6, 2005, Pages 610-615

  Russo, Patricia A ^a   Smith, Mark W ^b   Namjoshi, Madhav ^c  

^a MEDSTAT GROUP   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic agents; Costs; Drug comparisons; Olanzapine; Pharmacoeconomics; Risperidone; Schizophrenia

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 15044364794     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.6.610     Document Type: Article

References (16)

1. McIntyre CM, Simpson GM. Schizophrenia disorders. In: Rakel RE, ed. Conn's current therapy. Philadelphia: Saunders; 1995.
2. Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am. 1993; 16:413-23.
3. Wyatt RJ, Henter I, Leary MC et al. An economic evaluation of schizophrenia-1991. Soc Psychiatry Psychiatr Epidemiol. 1995; 30:196-205.
4. Mauskopf JA, David K, Grainger DL et al. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry. 1999; 60(suppl 19):14-9.
5. Beasley CM, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology. 1996; 14:111-23.
6. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol. 1995; 10(4):207-13.
7. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993; 26(4):121-4.
8. Markovitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999; 33(1): 73-85.
9. Edgell ET, Andersen SW, Johnstone BM et al. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics. 2000; 18:567-79.
10. Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Butt. 2002; 28:589-605.
11. Kasper S, Jones M, Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol. 2001; 16(4):189-96.
12. Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Manag Care Interface. 2002; 15(2):75-81.
13. Fuller MA, Shermock KM, Secic M et al. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr Serv. 2002; 53:855-60.
14. Rascati K, Johnsrud M, Crismon M et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics. 2003; 21:683-97.
15. Gibson PJ, Damler R, Jackson EA et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health. 2004; 7(1):22-35.
16. Zhao Z, Tunis S, Lage M. Medication treatment patterns following initiation on olanzapine versus risperidone. Clin Drug Invest. 2002; 22:741-9.